Sanofi: positive phase III data in IPT

(CercleFinance.com) - Sanofi announces that its Phase III LUNA 3 study of rilzabrutinib for the treatment of immune thrombocytopenia (IPT) met its primary endpoint, enabling patients to achieve a durable platelet response.


The safety profile of rilzabrutinib was consistent with that observed in previous studies. Regulatory submissions are planned in the US and the EU by the end of the year.

A serious autoimmune disease, IPT is characterised by the formation of antibodies that destroy platelets, and the disruption of platelet production leading to thrombocytopenia and increased bleeding episodes.


Copyright (c) 2024 CercleFinance.com. All rights reserved.